Cryoballoon ablation of atrial fibrillation in octogenarians: one year outcomes from the cryo global registry

• DOI: 10.1007/s10840-023-01680-z
• Publication Date: 2023-12-12T03:02:16Z
• Authors: Dennis Lawin; Thorsten Lawrenz; K. R. Julian Chun; Hong-Euy Lim; Valentine Obidigbo; Jada M. Selma; Peter Peytchev; Dinh Quang Nguyen; Csaba Földesi; Christoph Stellbrink
• Keywords: Registry; Octogenarians; 610; Catheter ablation; Cryoballoon; Atrial fibrillation; Article

Abstract Background Limited information is available on the safety and efficacy of cryoballoon ablation (CBA) in elderly patients with atrial fibrillation (AF). Moreover, global utilization of CBA in this population (≥ 80 years old) has not been reported. This study’s objectives were to determine the use, efficacy, and safety of CBA to treat octogenarians suffering from AF.

Methods In this sub-analysis of the Cryo Global Registry, 12-month outcomes of treating AF via CBA in octogenarians were compared to patients < 80 years old. Efficacy was evaluated as time to a ≥ 30 s atrial arrhythmia (AA) recurrence. Healthcare utilization was determined via repeat ablations and hospitalizations. Improvement upon disease burden was evaluated through patient reporting of symptoms and the EQ-5D-3L quality of life (QoL) survey.

Results The octogenarian cohort (n = 101) had a higher prevalence of females (51.5% vs 35.7%) and CHA2DS2-VASc scores (4.2 ± 1.3 vs 2.0 ± 1.5) compared to the control cohort (n = 1573, both p < 0.01). Even when adjusting for baseline characteristics and antiarrhythmic drug usage, freedom from AA recurrence at 12 months (80.6% vs 78.9%, HRadj:0.97 [95% CI:0.59–1.58], p = 0.90) was comparable between octogenarians and control, respectively. Similar serious adverse event rates were observed between octogenarians (5.0%) and control (3.2%, p = 0.38). The groups did not differ in healthcare utilization nor reduction of AF-related symptoms from baseline to follow-up, but both experienced an improvement in QoL at 12 months.

Conclusions Despite more age-related comorbidities, CBA is a safe and effective treatment for AF in octogenarians, with efficacy and adverse events rates akin to ablations performed in younger patients.

Clinical trial registration https://clinicaltrials.gov/ct2/show/NCT02752737

Graphical Abstract